PLoS ONE (Jan 2016)

A Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone Metastases.

  • Yu-Mu Chen,
  • Ying-Tang Fang,
  • Chien-Hao Lai,
  • Kun-Ming Rau,
  • Cheng-Hua Huang,
  • Huang-Chih Chang,
  • Tung-Ying Chao,
  • Chia-Cheng Tseng,
  • Wen-Feng Fang,
  • Chin-Chou Wang,
  • Yung-Che Chen,
  • Yu-Hsiu Chung,
  • Yi-Hsi Wang,
  • Mao-Chang Su,
  • Shih-Feng Liu,
  • Kuo-Tung Huang,
  • Hung-Chen Chen,
  • Ya-Chun Chang,
  • Yu-Ping Chang,
  • Meng-Chih Lin

DOI
https://doi.org/10.1371/journal.pone.0167923
Journal volume & issue
Vol. 11, no. 12
p. e0167923

Abstract

Read online

In the pre-tyrosine kinase inhibitors (TKIs) era, non-small cell lung cancer (NSCLC) patients with de novo bone metastases had a worse prognosis than those without. However, whether epidermal growth factor receptor (EGFR)-TKIs affect the outcomes of EGFR mutant NSCLC patients with de novo bone metastases has not been well studied thus far. We retrospectively studied the effect of EGFR mutation status and first-line EGFR-TKIs on patient outcomes and created a survival scoring system for NSCLC patients with de novo bone metastases. This retrospective study evaluated 1510 NSCLC patients diagnosed between November 2010 and March 2014. Among these patients, 234 patients had de novo bone metastases. We found that 121 of these 234 patients (51.7%) had positive EGFR mutation tests, and a positive EGFR mutation test significantly affected overall survival (OS) (EGFR mutant: 15.2 months, EGFR wild type: 6.5 months; p 3.1: 17.1months, LMR ≤ 3.1: 6.9months; p < 0.001). A positive EGFR mutation status reversed the poor outcomes of NSCLC patients with de novo bone metastases. A simple and useful survival scoring system including the above clinical parameters was thus created for NSCLC patients with de novo bone metastases.